JP2022545439A5 - - Google Patents
Info
- Publication number
- JP2022545439A5 JP2022545439A5 JP2022510921A JP2022510921A JP2022545439A5 JP 2022545439 A5 JP2022545439 A5 JP 2022545439A5 JP 2022510921 A JP2022510921 A JP 2022510921A JP 2022510921 A JP2022510921 A JP 2022510921A JP 2022545439 A5 JP2022545439 A5 JP 2022545439A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- prodrug
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962889797P | 2019-08-21 | 2019-08-21 | |
| US62/889,797 | 2019-08-21 | ||
| US202063027138P | 2020-05-19 | 2020-05-19 | |
| US63/027,138 | 2020-05-19 | ||
| US202063047251P | 2020-07-01 | 2020-07-01 | |
| US63/047,251 | 2020-07-01 | ||
| US202063053663P | 2020-07-19 | 2020-07-19 | |
| US63/053,663 | 2020-07-19 | ||
| PCT/US2020/047522 WO2021035188A1 (en) | 2019-08-21 | 2020-08-21 | Novel il-21 prodrugs and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022545439A JP2022545439A (ja) | 2022-10-27 |
| JP2022545439A5 true JP2022545439A5 (https=) | 2023-07-21 |
Family
ID=72432995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022510921A Pending JP2022545439A (ja) | 2019-08-21 | 2020-08-21 | 新規ｉｌ－２１プロドラッグおよびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220289822A1 (https=) |
| EP (1) | EP4017594A1 (https=) |
| JP (1) | JP2022545439A (https=) |
| CN (1) | CN115605504A (https=) |
| WO (1) | WO2021035188A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| CA3141626A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| CA3165927A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| CN118043079A (zh) * | 2021-06-17 | 2024-05-14 | 格治(香港)生物科技有限公司 | 免疫缀合物分子及其相关方法和组合物 |
| JP2024537846A (ja) * | 2021-09-30 | 2024-10-16 | ユノヴィア， カンパニー リミテッド | Ｉｌ－２１ｒ変異タンパク質を含有する免疫サイトカイン |
| JP2025508882A (ja) * | 2022-02-28 | 2025-04-10 | エクシリオ デベロップメント， インコーポレイテッド | 標的化サイトカインおよびその使用方法 |
| EP4504764A1 (en) * | 2022-05-26 | 2025-02-12 | Caribou Biosciences, Inc. | Cytokine-receptor fusions for immune cell stimulation |
| WO2024015960A1 (en) * | 2022-07-15 | 2024-01-18 | Xilio Development, Inc. | Engineered cleavable fc domain as carriers and methods of use thereof |
| CN117917438A (zh) * | 2022-10-21 | 2024-04-23 | 北京诺诚健华医药科技有限公司 | 抗体融合蛋白及其制备和应用 |
| WO2025191139A1 (en) * | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of her2-specific antigen binding proteins and cytokines |
| EP4671273A1 (en) * | 2024-06-26 | 2025-12-31 | Anaveon AG | INTERLEUKIN 21 PROXIMITY ACTIVATED |
| WO2026003219A1 (en) * | 2024-06-26 | 2026-01-02 | Anaveon AG | Proximity activated interleukin 21 |
| CN118546233B (zh) * | 2024-07-30 | 2024-10-18 | 成都微芯新域生物技术有限公司 | 白介素-21突变体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| DE10045592A1 (de) * | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US8211420B2 (en) | 2006-12-21 | 2012-07-03 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the IL-21 receptor |
| US20090304719A1 (en) * | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| US9487590B2 (en) * | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| AR099625A1 (es) | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| AU2015244025B2 (en) | 2014-04-08 | 2019-03-21 | Boston Pharmaceuticals Inc. | Binding molecules specific for IL-21 and uses thereof |
| CA2993429A1 (en) * | 2015-07-31 | 2017-02-09 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
| JP6981973B2 (ja) * | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| WO2018004338A1 (en) * | 2016-06-27 | 2018-01-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| EP3694885A1 (en) * | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| WO2020023702A1 (en) * | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
-
2020
- 2020-08-21 US US17/635,683 patent/US20220289822A1/en not_active Abandoned
- 2020-08-21 EP EP20768740.1A patent/EP4017594A1/en not_active Withdrawn
- 2020-08-21 CN CN202080077926.4A patent/CN115605504A/zh active Pending
- 2020-08-21 JP JP2022510921A patent/JP2022545439A/ja active Pending
- 2020-08-21 WO PCT/US2020/047522 patent/WO2021035188A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022545439A5 (https=) | ||
| Chen et al. | Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer | |
| Ahmed et al. | Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy | |
| Forsberg et al. | Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen | |
| ES3051373T3 (en) | Site-specific glycoengineering of targeting moieties | |
| JP2021515599A5 (https=) | ||
| ES2686692T3 (es) | Anticuerpo monoclonal anti CD146 | |
| ES2341625T3 (es) | Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas. | |
| TWI676681B (zh) | 具抗原專一性的t細胞及其用途 | |
| JP2021530243A5 (https=) | ||
| US20160208020A1 (en) | Peptide core-based multi-arm linkers | |
| US20230338565A1 (en) | Antibody drug conjugate, preparation method therefor and use thereof | |
| TWI817190B (zh) | 抗ｃ-Ｍｅｔ抗體藥物偶聯物及其應用 | |
| ES3052659T3 (en) | Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy | |
| TW201638108A (zh) | 抗ｃ－Ｍｅｔ抗體和抗ｃ－Ｍｅｔ抗體－細胞毒性藥物偶聯物及其醫藥用途 | |
| CN108473588A (zh) | 新颖抗密封蛋白抗体及使用方法 | |
| JP2021520832A (ja) | キレート化された放射性核種に対する抗体 | |
| US12466869B2 (en) | Targeting of multiple antigens with multiplex CAR T cells in solid and liquid malignancies | |
| ES3054945T3 (en) | Antibodies for chelated radionuclides and clearing agents | |
| Azadi et al. | Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines | |
| CN106459211A (zh) | 双功能抗体及其用途 | |
| US20150132306A1 (en) | HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES | |
| Pellegrino et al. | Impact of ligand size and conjugation chemistry on the performance of universal chimeric antigen receptor T-cells for tumor killing | |
| JP2024531446A5 (https=) | ||
| JP2023500293A (ja) | 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途 |